




May 7, 2026

# First Quarter 2026 Financial Results and Business Update



# Forward Looking Statements and Non-GAAP Measures

This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: our ability to effectively commercialize PALSONIFY to become a market leader or new standard of care; the expected growth of PALSONIFY sales; expected insurance coverage for PALSONIFY; our estimates relating to market size; the plans and timelines for approval of paltusotine outside the US; the plans and timelines for a Phase 3 program, regulatory filings or approval of paltusotine for carcinoid syndrome, for atumelnant for CAH and for atumelnant for ACTH-dependent Cushing’s syndrome; the ability of PALSONIFY to become a “blockbuster” therapy for acromegaly; the ability of atumelnant to become a “blockbuster” therapy for CAH; the ability of CRN09682 to become a “blockbuster” for neuroendocrine tumors or other SST2+ tumors; the plans and timelines for the clinical development of our drug candidates, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of additional research pipeline updates or the expected timing of the advancement of those programs; and the expected timing through which our cash, cash equivalents, and short-term investments will fund our operating plans or its operating cash burn guidance. In some cases, you can identify forward-looking statements by terms such as “may,” “believe,” “anticipate,” “could,” “should,” “estimate,” “expect,” “intend,” “plan,” “project,” “will,” “contemplate,” “predict,” “continue,” “forecast,” “aspire,” “lead to,” “designed to,” “goal,” “aim,” “potential,” “target,” “vision” or other similar terms or the negatives thereof.

These statements speak only as of the date of this presentation, involve known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation: the data available at the time of data analysis; estimates relating to market size and growth potential, which involve a number of assumptions and limitations, particularly about any projections, assumptions, and estimates of our future performance; the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk; the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of our clinical trials and nonclinical studies; regulatory developments or political changes, policies related to pricing and pharmaceutical drug reimbursement in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization; our ability to obtain and maintain intellectual property protection for our product candidates; we may use our capital resources sooner than we expect or our cash burn rate may accelerate; and other risks described under the heading “Risk Factors” in documents we file from time to time with the Securities and Exchange Commission. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

## Use of Non-GAAP Financial Measures

Crinetics has presented forward-looking non-GAAP operating expenses. Non-GAAP operating expenses exclude cost of product revenue, stock-based compensation, depreciation and amortization. Crinetics excludes cost of product revenue, stock-based compensation, depreciation and amortization because management believes the exclusion of these items is helpful to investors to evaluate Crinetics' recurring operational performance. Crinetics management uses this non-GAAP financial measure to monitor and evaluate its operating results and trends on an ongoing basis, and internally for operating, budgeting and financial planning purposes. The non-GAAP financial measure should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

# Introductory Remarks

## Scott Struthers

Founder & Chief Executive Officer





# Crinetics is an Endocrinology Powerhouse



**\$10.3M** in Palsonify™ net product revenue in 1Q2026



**Compelling trajectory** with continued strong execution on launch and clinical development



**World-class R&D** capabilities and capital efficient development with early-stage proof of concept



**Deep clinical stage pipeline** with blockbuster opportunities across acromegaly, CS, CAH and NETs



**\$1.3B** in cash, cash equivalents & investments



**IP protection** into 2040s



Culture dedicated to **patients** and **science**

# Commercial Update

**Isabel Kalofonos**

Chief Commercial Officer




# Driving Expansion on the Palsonify Launch

Once-Daily Oral  
**Palsonify**<sup>™</sup>  
(paltusotine) tablets

**\$10.3M**

**1Q2026 Net Product  
Revenue**

- ✓ **Strong demand across all patient segments**
- ✓ **Expanding breadth and depth**
- ✓ **Solid reimbursement coverage**



D, living with acromegaly


# Robust Launch Metrics Reflect Strong Execution

## Strong Demand from All Patient Segments

**232**

Enrollment Forms in Q1

### Share of Cumulative Enrollments



## Expanding Breadth and Depth of Prescribers

**263**

Cumulative Unique Palsonify Prescribers

**~50%**

Enrollments from Community Setting

## Solid Reimbursement Coverage

**~70%**

Patients on Therapy Reimbursed at End of Q1

**>60%**

Payer Coverage

**12 Months**

Duration of Most Prior Authorizations

Note: Data as of [March 31, 2026]. Source of business data is based on Komodo claims analysis and is anchored to enrollment forms. An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify. Enrollment forms metric also includes direct dispenses from pituitary treatment centers (PTCs) or community practices to patients.. Abbreviations: SoC = Standard of Care.


# Harnessing the Power of Patient Experience to Build Awareness and Advocacy for Palsonify

**Patient Ambassador Program features compelling stories from real Palsonify patients**

- ✓ Facilitates peer-to-peer engagement
- ✓ Empowers patients with knowledge to advocate for their own care

**CrinetiCARE® continues to be a valuable resource for patients**

- ✓ Supports persistence




# Robust Launch Metrics Reflect Strong Execution

## Strong Demand from All Patient Segments

**232**

Enrollment Forms in Q1

### Share of Cumulative Enrollments



## Expanding Breadth and Depth of Prescribers

**263**

Cumulative Unique Palsonify Prescribers

**~50%**

Enrollments from Community Setting

## Solid Reimbursement Coverage

**~70%**

Patients on Therapy Reimbursed at End of Q1

**>60%**

Payer Coverage


**12 Months**

Duration of Most Prior Authorizations

Note: Data as of [March 31, 2026]. Source of business data is based on Komodo claims analysis and is anchored to enrollment forms. An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify. Enrollment forms metric also includes direct dispenses from pituitary treatment centers (PTCs) or community practices to patients.. Abbreviations: SoC = Standard of Care.

# Palsonify Efficacy is Differentiated

Data from Published Indirect Treatment Comparison



# Improved Payer Coverage Based on Strength of Data and Value Proposition

➤ On Track to Achieve 75% of Covered Lives by 3Q2026



## Unprecedented Safety and Efficacy

Ability to achieve rapid biochemical and symptom control based on Phase 3 data



## Maintain Control

Limit patient and societal burden of uncontrolled acromegaly



## Optimize Treatment Paradigm

Ensure patients getting intended clinical benefit



## Improve Patient Adherence and Outcomes

Once-daily oral dosing and CrinetiCARE support

# Pipeline Updates

**Alan Krasner**


Chief Endocrinologist





# Raising Awareness of Palsonify and Differentiated Pipeline at Key Medical Congresses

April 22–24, 2026



**Once-Daily Oral Paltusotine in the Treatment of Adults With Acromegaly: Initial Real-World Experience**

Leena Shahla, MD<sup>1</sup>; Francesca Galbiati, MD<sup>2</sup>; Lewis S. Blevins, MD<sup>2</sup>; Kevin C. J. Yuen, MD<sup>3,4</sup>

<sup>1</sup>Duke University, Durham, NC; <sup>2</sup>University of California San Francisco, San Francisco, CA;

<sup>3</sup>Barrow Pituitary Center, Barrow Neurological Institute, Phoenix, AZ;

<sup>4</sup>University of Arizona College of Medicine and Creighton University School of Medicine, Phoenix, AZ

AACE 2026 Annual Meeting - April 22-24, 2026 - Las Vegas, NV



JUNE 13-16, 2026



- Presentations across differentiated portfolio, including
  - Long-term efficacy / safety of Palsonify in acromegaly
  - Full Phase 2 data for atumelnant in CAH
  - Additional patients from the Phase 1b/2a study of atumelnant in ADCS

# Financial Update

**Toby Schilke**

Chief Financial Officer



# Financial Results (unaudited)

(in millions)	Three Months Ended	
	March 31, 2026	December 31, 2025
Product Revenue, Net	\$ 10.3	\$ 5.4
Collaboration and License Revenue	0.4	0.7
<b>Revenues</b>	<b>\$ 10.7</b>	<b>\$ 6.2</b>
Cost of Product Revenue	(0.2)	(1.1)
R&D Expenses	(100.1)	(85.1)
SG&A Expenses	(50.8)	(53.7)
<b>Loss from Operations<sup>1</sup></b>	<b>\$ (140.4)</b>	<b>\$ (133.7)</b>

	April 23, 2026
Common Stock Outstanding	105.4 Million
Fully Diluted Share Count <sup>2</sup>	123.5 Million

<sup>1</sup>Financial results table does not depict non-operating items that are included in net losses

<sup>2</sup>Fully diluted share count includes outstanding options, unvested restricted stock units and shares expected to be purchased under our employee stock purchase plan

# \$1.3 Billion Cash Balance Funds Current Operating Plan and Strategic Initiatives

## Into 2030

Cash runway based on current operating plan

**\$600 Million - \$650 Million**

**GAAP** 2026 operating expense guidance

**\$480 Million - \$520 Million**

**Non-GAAP**<sup>1</sup> 2026 operating expense guidance

## Disciplined execution on multiple value-creating milestones including:

- Commercialization of PALSONIFY
- Pivotal readouts for ongoing clinical trials in carcinoid syndrome, adult CAH, pediatric CAH and ADCS
- Proof-of-concept for CRN09682
- Continued investments in early clinical-stage studies and discovery efforts

<sup>1</sup>Non-GAAP operating expenses exclude cost of product revenue, stock-based compensation, and depreciation and amortization. Crinetics is unable to reconcile forward-looking non-GAAP operating expenses to the most directly comparable GAAP measure without unreasonable effort because the items that are being excluded are difficult to predict or a range of results could lead to disclosure that would be imprecise or potentially misleading. Material changes to any one of the exclusions could have a significant effect on our forward-looking estimates and GAAP results. Such items include cost of product revenue, stock-based compensation, depreciation and amortization.

# Closing Remarks

## Scott Struthers

Founder & Chief Executive Officer



# Upcoming Milestones

★ Potential 2026 Milestone

## Paltusotine

- ★ Commercial execution of PALSONIFY in the U.S.
- ★ Advancing paltusotine in other geographies
- Phase 3 CAREFNDR readout in carcinoid syndrome

## Atumelnant

- ★ Longer duration data from OLE portion of TouCAHn in adult CAH
- Phase 3 CALM data in adult CAH
- ★ Phase 2/3 BALANCE data in pediatric CAH (data update after Phase 2 portion)
- ★ Additional data from ongoing Phase 1b/2a study in ADCS
- ★ Phase 2/3 EQUILIBRIUM trial initiation in ADCS (data update after Phase 2 portion)

## CRN09682

- ★ Phase 1/2 BraveSST2 dose escalation/expansion in NETs

## Early-Stage

- ★ Continued innovation from world-class discovery team



**Thank You**

